The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
New Vaccine Development Establishing Priorities, Volume I: Diseases of Importance in the United States
Hemophilus influenzae type B, 245 –248
hepatitis A virus, 258
hepatitis B virus, 272 –276
herpes simplex viruses, 301 –310
Herpesvirus varicellae vaccine, 334 –339
influenza viruses, 358 –362
Neisseria gonorrhoeae , 378 –382
parainfluenza viruses, 393 –395
pertussis, 180 –181
respiratory syncytial virus, 405 –407
rotavirus, 420 –421
streptococcus group B, 434 –437
Cost per dose, 66 , 141 , 144
Cost-effectiveness analysis, 22 , 24 –25 , 149 , 150
Cost-utility analysis, 22
Cytomegalovirus (CMV)
anticipated vaccine utilization, 226 –227
control suitability, 218 –219
cost of illness, 227 –232
disease burden, 199 –215
disease description, 198
host immune response, 199
pathogen description, 199
total disease burden values, 215
vaccine development prospects, 224 –226
vaccine preventable illness, 219 –224
vaccine target populations, 215 , 218
D
Decision analysis, 21 , 24 , 149
Delay of benefits, 11 , 101
Delivery requirements, 66
Delphi method, 25
Development costs, 64
Direct costs, 50 , 52 –54 , 92
Discounting, 11 , 30 , 100 –103 , 135 –137
Disease burden
coccidioidomycosis, 185 –188
conclusions on, 57
cytomegalovirus, 199 –215
equity issues, 121
findings on, 54
Hemophilus influenzae type B, 236 –240
hepatitis A virus, 253 –255
hepatitis B virus, 263 –266
herpes simplex viruses, 281 –294
Herpesvirus varicellae , 315 –323
influenza viruses, 344 –351
limitations of, 48 –49 , 54 , 57
multiple profile approach, 122
Neisseria gonorrhoeae , 370 –373
parainfluenza viruses, 386 –388
pertussis, 174 , 175
recommendations for, 57
respiratory syncytial virus, 398 –400
rotavirus, 412 –417
streptococcus group B, 425 –430
system elements, 6 , 39 –49
trend factors, 96
value judgments and, 49 –50
Disease burden costs
calculation of, 12 –13 , 50 , 52 –54
coccidioidomycosis, 194
cytomegalovirus, 227 –232
Hemophilus influenzae type B, 245 –247
hepatitis A virus, 258 –259
hepatitis B virus, 272 –274
herpes simplex viruses, 301 –306
Herpesvirus varicellae , 334 –339
influenza viruses, 359 –360
Neisseria gonorrhoeae , 378 –380
parainfluenza viruses, 393 –394
respiratory syncytial virus, 406
rotavirus, 420 –421
streptococcus group B, 434 –435
Dominance rule, 14 –15 , 34 , 128
E
Efficacy, 65
Entamoeba histolytica , 157 –158
Epstein-Barr virus (EBV), 158
Equity issues, 121
Escherichia coli , 158 –159
Expected annual health benefits, 94 , 110
Expert judgments, 25 , 75
G
Giardia lamblia , 159
Gonorrhea. See Neisseria gonorrhoeae
Gram-negative bacteria, 159
H
Health belief model (HBM), 69 –71 , 74 , 75 , 83 , 89 .
See also Anticipated vaccine utilization
Health benefits and costs
analytical methods, 29 –34
assumptions and explanations, 95 –109
calculation of, 11 , 92 –95
equity issues, 121
ranking and, 34 –37
results of analysis, 110 –120
See also Vaccine preventable illness;
Vaccine preventable illness costs
